The continued expansion of GLP-1 weight-loss therapies has introduced both commercial opportunity and evolving legal and regulatory considerations across the health care landscape. Novo Nordisk’s (“Novo”) recent federal lawsuit against Hims & Hers (“Hims”) illustrates how brand manufacturers may increasingly use patent and regulatory frameworks to challenge the marketing and sale of compounded versions of these products. This case may signal a broader shift in how compounding practices, telehealth platforms and pharmaceutical patent rights intersect.
On Monday, February 9,
Continue Reading Evolving Legal and Regulatory Considerations for Weight Loss Therapies


